Hosts of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives recorded a special edition episode with Jake Leach, chief operating officer of Dexcom. The episode itself represents a follow-up to a conversation a year ago at International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) 2023, where Leach discussed the ongoing global rollout of the Dexcom G7 and how he expected expanded coverage of the device to open doors to greater personalization of care for people with diabetes.

In the current episode, Leach and hosts touch upon the Stelo clearance, its accuracy relative to other CGM devices, plans for rollout and pricing, the importance of increased accessibility of CGM technology, and the push for greater accuracy in glucose monitoring devices.

Video Version: https://www.hcplive.com/view/diabetes-dialogue-stelo-news-and-dexcom-cgm-updates-with-jake-leach

00:30 - Jake Leach Introduction

01:20 - Dexcom Stelo Overview

06:25 - Differences vs G6 and G7

 14:45 - Direct to Watch Technology

20:05 - Future of Dexcom Portfolio